Tags

Type your tag names separated by a space and hit enter

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Curr Med Res Opin. 2009 Sep; 25(9):2159-65.CM

Abstract

OBJECTIVE

To assess the effects of tolterodine extended release (ER) on patient-reported outcomes (PROs) in sexually active women with overactive bladder (OAB) and urgency urinary incontinence (UUI).

RESEARCH DESIGN AND METHODS

This multicenter, double-blind, placebo controlled trial included 411 women aged > or =18 years reporting OAB symptoms for > or =3 months; > or =8 micturitions per 24 hours (including > or =0.6 UUI episodes and > or =3 OAB micturitions) in 5-day bladder diaries at baseline, and being in a sexually active relationship for > or =6 months. Subjects randomized to placebo or tolterodine ER completed validated OAB- or incontinence-specific questionnaires, including the Patient Perception of Bladder Condition (PPBC), Overactive Bladder Questionnaire (OAB-q), Urgency Perception Scale (UPS), and the Incontinence Impact Questionnaire (IIQ) at baseline and week 12, as well as the Perception of Treatment Benefit and Treatment Satisfaction questions at week 12. This study is registered with ClinicalTrials.Gov (identifier: NCT00143481).

RESULTS

The mean age of enrolled women was approximately 48 years. Compared with placebo, the tolterodine ER group reported significant baseline to week 12 improvements in PPBC responses (p = 0.0048); OAB-q Symptom Bother, total Health-Related Quality of Life (HRQL), and HRQL domain scores (all p < 0.05); IIQ Emotional Health domain scores (p < 0.05); proportions of subjects reporting treatment benefit (79 vs. 54%; p < 0.0001) and satisfaction (78 vs. 59%; p < 0.0001). Improvements on the UPS were not significantly different.

CONCLUSIONS

Tolterodine ER treatment was associated with improvements in multiple OAB- and incontinence-specific PROs in a sexually active, relatively young, and racially diverse population of women. The findings provide clinicians with new insights into the impact of OAB and its treatment on HRQL in this population, which has been underrepresented in previous OAB studies. Study limitations include a potential underestimation of the impact of OAB symptoms resulting from the exclusion of women who may not be sexually active because of their urinary symptoms.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA. RRogers@salud.unm.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19601704

Citation

Rogers, Rebecca G., et al. "Effects of Tolterodine ER On Patient-reported Outcomes in Sexually Active Women With Overactive Bladder and Urgency Urinary Incontinence." Current Medical Research and Opinion, vol. 25, no. 9, 2009, pp. 2159-65.
Rogers RG, Bachmann G, Scarpero H, et al. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Curr Med Res Opin. 2009;25(9):2159-65.
Rogers, R. G., Bachmann, G., Scarpero, H., Jumadilova, Z., Sun, F., Morrow, J. D., Guan, Z., & Bavendam, T. (2009). Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Current Medical Research and Opinion, 25(9), 2159-65. https://doi.org/10.1185/03007990903103279
Rogers RG, et al. Effects of Tolterodine ER On Patient-reported Outcomes in Sexually Active Women With Overactive Bladder and Urgency Urinary Incontinence. Curr Med Res Opin. 2009;25(9):2159-65. PubMed PMID: 19601704.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. AU - Rogers,Rebecca G, AU - Bachmann,Gloria, AU - Scarpero,Harriette, AU - Jumadilova,Zhanna, AU - Sun,Franklin, AU - Morrow,Jon D, AU - Guan,Zhonghong, AU - Bavendam,Tamara, PY - 2009/7/16/entrez PY - 2009/7/16/pubmed PY - 2009/12/16/medline SP - 2159 EP - 65 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 25 IS - 9 N2 - OBJECTIVE: To assess the effects of tolterodine extended release (ER) on patient-reported outcomes (PROs) in sexually active women with overactive bladder (OAB) and urgency urinary incontinence (UUI). RESEARCH DESIGN AND METHODS: This multicenter, double-blind, placebo controlled trial included 411 women aged > or =18 years reporting OAB symptoms for > or =3 months; > or =8 micturitions per 24 hours (including > or =0.6 UUI episodes and > or =3 OAB micturitions) in 5-day bladder diaries at baseline, and being in a sexually active relationship for > or =6 months. Subjects randomized to placebo or tolterodine ER completed validated OAB- or incontinence-specific questionnaires, including the Patient Perception of Bladder Condition (PPBC), Overactive Bladder Questionnaire (OAB-q), Urgency Perception Scale (UPS), and the Incontinence Impact Questionnaire (IIQ) at baseline and week 12, as well as the Perception of Treatment Benefit and Treatment Satisfaction questions at week 12. This study is registered with ClinicalTrials.Gov (identifier: NCT00143481). RESULTS: The mean age of enrolled women was approximately 48 years. Compared with placebo, the tolterodine ER group reported significant baseline to week 12 improvements in PPBC responses (p = 0.0048); OAB-q Symptom Bother, total Health-Related Quality of Life (HRQL), and HRQL domain scores (all p < 0.05); IIQ Emotional Health domain scores (p < 0.05); proportions of subjects reporting treatment benefit (79 vs. 54%; p < 0.0001) and satisfaction (78 vs. 59%; p < 0.0001). Improvements on the UPS were not significantly different. CONCLUSIONS: Tolterodine ER treatment was associated with improvements in multiple OAB- and incontinence-specific PROs in a sexually active, relatively young, and racially diverse population of women. The findings provide clinicians with new insights into the impact of OAB and its treatment on HRQL in this population, which has been underrepresented in previous OAB studies. Study limitations include a potential underestimation of the impact of OAB symptoms resulting from the exclusion of women who may not be sexually active because of their urinary symptoms. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/19601704/Effects_of_tolterodine_ER_on_patient_reported_outcomes_in_sexually_active_women_with_overactive_bladder_and_urgency_urinary_incontinence_ L2 - http://www.tandfonline.com/doi/full/10.1185/03007990903103279 DB - PRIME DP - Unbound Medicine ER -